Thicker than ever: The 21st edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
Danish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AG’s anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).
Swiss Lonza announced that CEO Marc Funk is leaving the company. Chairman Albert Baehny will take over as CEO on an ad interim basis until a successor is found.
Swiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines.
Expedeon has sold its immunology and proteomics business activities to global life sciences company Abcam. Abcam is paying €120m in cash for the business.
Fibra-Cel® Disks are an advanced, solid support material for the efficient growth of mammalian and insect cells in bioreactors. They are devised to improve the cultivation of anchorage-dependent as well as suspension cells. Fibra-Cel Disks can be used also for perfusion cell culture with the Eppendorf packed-bed impeller – available for glass, stainless steel, and single-use bioreactors.
Autoimmunity specialist SciRhom GmbH has kicked of a first-in-class antibody development programme targeting iRhom2.